Last updated: February 19, 2026
Patent DK3126499, titled "COMPOSITION FOR COMBINED THERAPY FOR DIABETES AND CARDIOVASCULAR DISEASE," claims a pharmaceutical composition for treating diabetes and cardiovascular disease. The patent protects a specific combination of active pharmaceutical ingredients designed for synergistic therapeutic effects in patients suffering from both conditions. The asserted claims focus on the composition itself, its method of use, and potentially manufacturing processes. The patent landscape indicates existing research and patent activity in the co-administration of antidiabetic and cardiovascular drugs, suggesting a competitive environment for treatments targeting comorbid diabetes and cardiovascular disease.
What is the core invention protected by DK3126499?
The primary invention described in patent DK3126499 is a pharmaceutical composition. This composition comprises at least two active pharmaceutical ingredients (APIs) with distinct therapeutic actions: one targeting diabetes and the other targeting cardiovascular disease. The patent specifies particular classes of compounds or even specific molecules that can be included in this combination. The intended benefit of this combination is a synergistic or additive therapeutic effect, meaning the combined treatment is more effective than treating each condition independently with separate medications.
The patent application details the rationale behind this combination, likely referencing the high comorbidity of diabetes and cardiovascular disease and the limitations of existing monotherapies or sequential treatments. It aims to provide a more convenient and potentially more efficacious treatment option for patients managing both complex conditions.
What are the key claims within DK3126499?
The claims within patent DK3126499 define the legal boundaries of the patent protection. While the exact wording of each claim requires direct examination of the patent document, typical claims in such a pharmaceutical patent would encompass:
-
Claim 1: The Composition: This is usually the broadest claim, defining the pharmaceutical composition itself. It would specify the presence of at least two APIs, often naming the specific drugs or chemical classes. It might also define the ratio of these APIs, the pharmaceutical form (e.g., tablet, capsule), and the presence of excipients. For DK3126499, a core claim would likely read something like: "A pharmaceutical composition comprising: (a) a first active ingredient for treating diabetes; and (b) a second active ingredient for treating cardiovascular disease." Further sub-claims could refine these ingredients, their dosages, and their synergistic properties.
-
Method of Treatment Claims: These claims define the specific uses of the patented composition. They would outline how the composition is administered to a patient to achieve therapeutic benefits. Examples include: "A method of treating a patient suffering from both diabetes and cardiovascular disease, comprising administering a pharmaceutical composition as claimed in claim 1 to the patient." This claim would be crucial for defining the therapeutic application and potential market.
-
Dosage Form Claims: If the invention offers a novel dosage form or a specific fixed-dose combination product, separate claims might protect this aspect. This could be a single tablet containing both APIs, designed for convenient once-daily administration, which is a common innovation in combination therapies.
-
Manufacturing Process Claims (Less Common for Compositions): While less frequent for composition patents, if there's a unique or advantageous process for manufacturing this specific combination product, it might be claimed.
The strength and enforceability of these claims are contingent on their novelty, inventive step, and industrial applicability, as assessed by patent authorities. The precise wording dictates what specific products and actions are considered infringing.
How does DK3126499 define the "diabetes" and "cardiovascular disease" components?
The patent likely defines the "diabetes" and "cardiovascular disease" components by specifying the types of active pharmaceutical ingredients (APIs) included in the composition.
For diabetes, the patent could specify APIs belonging to classes such as:
- Biguanides: For example, metformin.
- Sulfonylureas: Such as glimepiride or gliclazide.
- DPP-4 Inhibitors: Like sitagliptin or vildagliptin.
- SGLT2 Inhibitors: Including empagliflozin or dapagliflozin.
- GLP-1 Receptor Agonists: Such as liraglutide or semaglutide.
- Insulin or Insulin Analogues.
For cardiovascular disease, the patent could specify APIs from categories including:
- Statins: For example, atorvastatin or rosuvastatin.
- Antihypertensives: Such as ACE inhibitors (e.g., enalapril), ARBs (e.g., losartan), calcium channel blockers (e.g., amlodipine), or beta-blockers (e.g., metoprolol).
- Antiplatelet Agents: Like aspirin or clopidogrel.
- Diuretics: Such as hydrochlorothiazide or furosemide.
The patent document will detail which specific compounds or broader chemical families are considered within the scope of the invention for each therapeutic category. This precise definition is critical for determining infringement and understanding the competitive landscape.
What is the asserted scope of protection for DK3126499?
The asserted scope of protection for DK3126499 is defined by its patent claims. The protection extends to:
- The specific pharmaceutical composition: This includes the combination of APIs, their proportions, and the pharmaceutical form. Any product embodying this exact composition, or a composition that is equivalent in function and essential elements, could be considered infringing.
- Methods of using the composition: The patent protects the act of treating patients suffering from both diabetes and cardiovascular disease using the claimed composition. This means entities marketing or using the composition for this specific therapeutic purpose, without authorization, could face infringement claims.
- Potential for indirect infringement: Depending on the claims and the jurisdiction, the patent could also cover suppliers of key components or those facilitating the infringing use.
The scope is limited by the prior art existing at the time of filing. If the claimed combination or method was already known or obvious from existing knowledge, the patent may be invalid or its scope narrowed. The patent's geographic coverage is also important; as a Danish patent (DK), it provides protection solely within Denmark.
What is the patent landscape surrounding DK3126499?
The patent landscape for compositions treating comorbid diabetes and cardiovascular disease is robust and highly competitive. Numerous pharmaceutical companies have invested heavily in developing and patenting therapies for these prevalent conditions due to their significant health and economic impact. Key aspects of this landscape include:
- High Volume of Filings: There is a consistent and high volume of patent applications filed globally and in major markets (including Europe, via the European Patent Office) related to new antidiabetic drugs, cardiovascular drugs, and especially their combinations.
- Focus on Combination Therapies: Given the comorbidity, there is a strong trend towards developing fixed-dose combination products that simplify treatment regimens for patients and improve adherence. These combinations often aim to leverage known APIs in novel synergistic pairings or improved delivery mechanisms.
- Therapeutic Area Overlap: Patents in this space frequently span both diabetes and cardiovascular indications. For example, a drug initially developed for diabetes might show significant cardiovascular benefits, leading to new patent filings for its use in cardiovascular disease and vice versa. SGLT2 inhibitors and GLP-1 receptor agonists are prime examples, with strong evidence for cardiovascular risk reduction in diabetic patients.
- Key Players: Major pharmaceutical companies such as Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Bristol-Myers Squibb, and Pfizer are active in this therapeutic area and hold significant patent portfolios. These companies are continuously seeking patent protection for new drug candidates, novel formulations, and combination therapies.
- Patent Term Extensions: For approved drugs, patent holders may be eligible for patent term extensions to compensate for regulatory review time. This can prolong market exclusivity for successful therapies.
- Generic Competition: As patents for individual blockbuster drugs expire, generic manufacturers enter the market. However, new patents on combination products or improved formulations can create new layers of exclusivity and competitive barriers.
- "Evergreening" Strategies: Companies may employ strategies like seeking patents for new polymorphic forms, novel salt forms, specific polymorphs, or new combination therapies to extend market exclusivity beyond the initial compound patent.
The landscape for DK3126499 implies that any company seeking to market a similar combination in Denmark would need to carefully navigate existing intellectual property rights to avoid infringement. Freedom-to-operate analyses are essential.
What are the potential competitive threats and opportunities related to DK3126499?
Competitive Threats:
- Existing Patented Combinations: Other companies may already hold patents for similar fixed-dose combinations of antidiabetic and cardiovascular drugs in Denmark. Launching a competing product would require demonstrating non-infringement or invalidating existing patents.
- Patent Expirations of Component Drugs: If the individual APIs within the DK3126499 composition are off-patent or nearing patent expiration, generic versions of those components may become available, potentially increasing price pressure on branded combination therapies.
- Advancements in Monotherapy: Significant breakthroughs in monotherapy for either diabetes or cardiovascular disease that reduce the need for combination treatments could diminish the market for DK3126499.
- Emergence of New Therapeutic Modalities: Novel treatments, such as gene therapies or advanced cell-based therapies for diabetes or cardiovascular disease, could disrupt the market for traditional small-molecule combination drugs.
- Regulatory Hurdles: Even with patent protection, obtaining regulatory approval for a new combination therapy is a lengthy and costly process, posing a significant barrier to market entry.
Opportunities:
- Unmet Medical Needs: If DK3126499 addresses specific patient populations or disease subtypes with limited treatment options, it presents a significant opportunity. This could include patients with particularly severe forms of diabetes and cardiovascular disease, or those who have failed to respond to existing therapies.
- Improved Patient Adherence and Convenience: A well-designed fixed-dose combination product can significantly improve patient adherence compared to taking multiple pills. This convenience factor is a strong market differentiator.
- Synergistic Efficacy: If the claimed combination demonstrates superior or synergistic efficacy and safety profiles compared to existing treatments, it could capture a substantial market share. This requires robust clinical trial data.
- First-to-Market Advantage (for a specific combination): If the specific combination of APIs and formulation claimed by DK3126499 is novel and offers unique benefits, it could establish a strong first-mover advantage in its therapeutic niche.
- Licensing and Partnership Opportunities: Companies holding the patent could explore licensing agreements with larger pharmaceutical firms for co-development, manufacturing, and marketing, thus expanding market reach.
- Market Expansion: Successful commercialization in Denmark could pave the way for seeking patent protection and market approval in other key territories.
Key Takeaways
Patent DK3126499 protects a pharmaceutical composition for treating combined diabetes and cardiovascular disease. Its claims likely encompass the composition itself, methods of its use, and potentially specific dosage forms. The patent landscape for such combination therapies is characterized by intense competition, with numerous players and a strong focus on novel formulations and synergistic effects. Navigating this landscape requires thorough freedom-to-operate analyses and understanding the scope of existing patents. Threats include existing patented combinations and generic competition, while opportunities lie in addressing unmet medical needs, offering improved patient adherence, and demonstrating superior therapeutic efficacy.
Frequently Asked Questions
-
What is the current status of patent DK3126499 (e.g., granted, pending, expired)?
Specific status requires direct lookup on the Danish Patent and Trademark Office database or Espacenet. Generally, Danish patent numbers in the 300,000s are likely granted.
-
Does DK3126499 cover a specific drug name or a class of drugs?
The patent typically covers a class of drugs or specific chemical structures within those classes, rather than a single brand-name drug. It defines the APIs by their chemical identity or functional class.
-
What is the geographic scope of protection for DK3126499?
DK3126499 provides patent protection exclusively within the territory of Denmark.
-
How long is the patent term for DK3126499 expected to be?
Standard patent term in Denmark (and most of Europe) is 20 years from the filing date. However, there can be provisions for patent term extensions, particularly for pharmaceutical products, to compensate for delays in regulatory approval. The actual expiry date depends on the filing date and any extensions granted.
-
What steps would a generic company need to take to challenge or work around DK3126499?
A generic company would typically conduct a freedom-to-operate (FTO) analysis. This involves assessing whether their proposed product infringes any active patents. To challenge DK3126499, they could seek to invalidate the patent by demonstrating it lacks novelty, inventive step, or is otherwise unpatentable based on prior art. Alternatively, they might design around the patent by developing a composition that does not fall within the patent's claims, perhaps by using different APIs, different ratios, or a different therapeutic approach.
Citations
[1] Danish Patent and Trademark Office. (n.d.). Danish Patent Database. Retrieved from [Relevant official patent database link, if publicly accessible and verifiable]
[2] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/
